Top

Published in:

01-04-2015 | Research

Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver

Authors: Taiseer R. Ibrahim, Samar M. Abdel-Raouf

Published in: Pathology & Oncology Research | Issue 2/2015

Abstract

Hepatocellular carcinoma (HCC) remains a common malignant cancer worldwide, it is considered the fifth most common malignant cancer. On the other hand, metastatic tumors are widespread in the liver , with metastatic adenocarcinoma (MA) constituting the greatest part, therefore differentiation of HCC from MA is a frequent problem facing the pathologist especially in liver fine-needle aspiration biopsies. Evaluating the diagnostic value of glypican-3 (GPC-3) and HepPar-1 immunostaining in differentiating hepatocellular carcinoma from metastatic tumors in liver cell block material. Fourty eight cell blocks prepared from FNA from the liver ( 30 cases HCC, 18 cases metastatic carcinoma in liver ) stained by Glypican -3 and HepPar-1 immunohistochemical markers. Glypican-3 was immunoexpressed in 97 % of cases of HCC while all cases of metastatic carcinoma were negative . HepPar-1 was expressed in 93 % of cases of HCC and 11 % of metastatic carcinoma of the liver . In this study the sensitivity of GPC3 in the diagnosis of HCC in cytological material was 96.7% and the specificity was 100% while the sensitivity and specificity of HepPar-1 was 93.3 % and 88.9 % respectively. Immunohistochemical staining for GPC-3 in cell block material of the liver is highly sensitive and specific and it is a valuable tool capable of differentiating HCC from most of metastatic tumors of the liver.

El Serag HB (2002) Hepatocellullar carcinoma:an epidemiologic view. J Clin Gastroenterol 35(5 suppl 2):S72–S78CrossRefPubMed

Waly Raphael S, Yangde Z and Yuxiang C (2012)Hepatocellular carcinom :focus on different aspects of management.ISRN Oncol;2012: 421673

National Cancer Instiute Cairo (2010) Cancer registry 2002-2007. Website: www.Nci.edu.eg.data

Anwar AA, Khaled HM, Amra H et al (2008) Changing pattern of hepatocellullar carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 659:176–184CrossRefPubMed

Aleem E, Elshayeb A, Elhabschi N, Mansour AR, Gowily A, Hela A (2012) Serum IGFBP-1 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection. Oncol Lett 3(3):704–712PubMedCentralPubMed

Choi BI (2004) The current status of imaging diagnosis of hepatocellullar carcinoma. Liver Transpl 10(2 suppl 1):S20–S25CrossRefPubMed

Ligato S, Mandich D, Richard W (2008) Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol 21:626–631CrossRefPubMed

Kakar S, Gown AM, Goodman ZD, Ferrell LD (2007) Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Archit Pathol Lab 131:1648–1654

Kandil D, Cooper K (2009) Glypican-3 a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol 16:125–129CrossRefPubMed

10.

Yamauchi N, Watanabe A, Hishinuma M et al (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18:1591–1598PubMed

11.

Suriawinata A, Thung SN (2010) Molecular signature of early hepatocellular carcinoma. Oncol 78:36–39CrossRef

12.

Anatelli F, Chuang S, Yang X, Wang H (2008) Value of glypican 3 immunostaining in the diagnosis of hepatocellullar carcinoma on needle biopsy. Am J Clin Pathol 130:219–223CrossRefPubMed

13.

Di Tommaso L, Franchi G, Park YN et al (2007) Diagnostic value of HSP70, glypican 3 and glutamine synthetase in hepatocellullar nodules in cirrhosis. Hepatology 45:725–734CrossRefPubMed

14.

Shafizadeh N, Ferrell LD, Kakar S (2008) Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 21:1011–1018CrossRefPubMed

15.

Yan BC, Gong C, Song J et al (2010) Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 34:1147–1154CrossRefPubMedCentralPubMed

16.

Hajosi-Kalcakosz S, Dezso K, Buggik E et al (2012) Enhancer of zeste homologue 2(EZH2) is a reliable immunohistochemical marker to differentiate malignant and bengin hepatic tumors. Diagn Pathol 7:86CrossRefPubMedCentralPubMed

17.

Thiese ND,Curado MP and Franceschi S (2010) Hepatocellullar carcinoma .In WHO classification of tumors of the digestive system .4th edition .Edited by Bosman FT, Carneiro F,Hruban RH, Thiese ND. Lyon, France IARC Press:205-216

18.

Ishak KG,Goodman ZD and Stocker JT (2001) Tumor of liver and intrahepatic bile ducts: in :Atlas of tumor pathology, 3rd series,Fascicle 31. Washington, DC: Armed Forces Institute of Pathology; 9-48

19.

Sternberg SS, Mills SE, Carter D (2010) Sternberg s diagnostic surgical pathology, 5th edn. Wolter Kluwer Lippincott Williams& Wilkins, Philadelphia

20.

Wee A (2011) Fine needle aspiration biopsy of hepatocellullar carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. Cytopathology 22:287–305CrossRefPubMed

21.

Ceyhan K, Kupana SA, Bektas M et al (2007) The diagnostic value of on-site cytopathological evaluation and cell block preparation in fine needle aspiration cytology of liver masses. Cytopathology 17:267–274CrossRef

22.

Shiran MS, Isa MR, Sherina MS, Rampal L, Hairuszah I, Sabariah AR (2006) The utility of hepatocyte paraffin-1 antibody in the immunohistochemical distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma. Malays J Pathol 28(2):87–92PubMed

23.

Shirakawa H, Kuronuma T, Nishimura Y (2009) Glypican-3 as a useful diagnostic marker for a component of hepatocellullar carcinoma in human liver cancer. Int J Oncol 34:649–656PubMed

24.

Abdelgawad IA, Mossallam GI, Radwan NH, Elzawahry HM, Elhifnawy NM (2013) Can glypican-3 be diagnostic for early hepatocellular carcinoma among Egyptian patients. Asian Pac J Cancer Prev 14:7345–7349CrossRefPubMed

25.

Zaakook M, Ayoub M, Sinna EA, El-Sheik S (2013) Role of glypican-3 immunocytochemistry in differentiatating hepatocellullar carcinoma from metastatic carcinima of the liver utilizing fine needle aspiration cytology. J Egypt Nati Inst Dec 25(4):173–80CrossRef

26.

Nasser A, Cohen C, Siddiqui MT (2009) Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine- needle aspiration biopsies. Diagn Cytopathol 37(9):629–35CrossRef

27.

McKnight R, Nassar A, Cohen C, Siddiqui MT (2012) Arginase-1: a novel immunohistochemical marker of hepatocellullar differentiation in fine needle aspiration cytology. Cancer Cytopathol 120:223–229CrossRefPubMed

28.

Fujiwara M, Kwok S, Yano H, Pai RK (2012) Arginase-1 is a more sensitivemarker of hepatic differentiation than HepPar-1 and Glypican-3 in fine needle aspiration biopsies. Cancer Cytopathol 120:230–237CrossRefPubMed

29.

Timek DT, Shi J, Liu H, Lin F (2012) Arginase-1, HepPar-1 and Glypican-3 are the most effective panel of markers in differentiating hepatocellular carcinoma from metastatic tumor on fine needle aspiration specimens. Am J Clin Pathol 138:203–210CrossRefPubMed

30.

Radwan NA, Ahmed NS (2012) The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol 7:149CrossRefPubMedCentralPubMed

Title: Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver
Authors: Taiseer R. Ibrahim
Samar M. Abdel-Raouf
Publication date: 01-04-2015
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9830-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

The Evaluation of WBP2NL-Related Genes Expression in Breast Cancer

Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms

Revealing the Potential Pathogenesis of Glioma by Utilizing a Glioma Associated Protein-Protein Interaction Network

Identification of Differently Expressed Genes with Specific SNP Loci for Breast Cancer by the Integration of SNP and Gene Expression Profiling Analyses

Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma

Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer